US-based InDevR, Inc., a leading provider of analytical tools for vaccine quality control and testing, has teamed up with Sino Biological, Inc., a biotechnological firm listed on the Shenzhen stock exchange, which specialises in biological research reagents and related technical services.
China-based Sino Biological, Inc. has concluded the acquisition of Canadian biotechnology company SignalChem Biotech Inc. (SCB). Sino Biological has acquired 100% of SCB shares in a deal valued at $48 million, inclusive of all assets, assumed indebtedness, and net of cash deposits.
Sino Biological Announces Services Partnership with Rapid Novor
HOUSTON, TX, Oct. 09, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire ” Sino Biological, Inc. (œSino Biological or the œCompany), a biotechnology company listed on the Shenzhen stock exchange subsidiary...
Houston, TX, Nov. 21, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Sino Biological, Inc. (“Sino Biological” or the “Company”), a biotechnology company listed on the Shenzhen stock exchange subsidiary ChiNext (SZSE: 301047), which provides biological research reagents and related technical contract research services, is pleased to announce the formal signing of a lease with Hines and initiation of construction on its new Center for Bioprocessing (C4B) at its Levit Green facility in Houston, Texas USA.
Beijing, China, March 28, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Sino Biological, Inc.(“Sino Biological” or the “Company”), a biotechnology company listed on the Shenzhen stock exchange...
Beijing, China, March 15, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Sino Biological, Inc. (“Sino Biological” or the “Company”), a biotechnology company listed on the Shenzhen stock exchange...
BEIJING, China, Dec. 7, 2021 /PRNewswire/ -- Sino Biological, Inc. (http://www.sinobiological.com; SHE: 301047) announced today that it has launched a panel of research reagents for the newly identified Omicron variant (B.1.1.529) of the SARS-COV-2 virus, which quickly raised concerns around the world because of the high number of mutations it carries, especially the 30-plus mutations on the Spike protein.
BEIJING — China, August 16, 2021 - Sino Biological, Inc (“Sino Biological” or the “Company”), a biotechnology company which provides biological research reagents and related technical contract research services, announced a successful listing on the Shenzhen Stock Exchange subsidiary ChiNext under the stock abbreviation Sino Biological and stock code 301047. A total of 17 million shares were issued for a total of 4.98 billion RMB raised during this initial public offering.